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Fatty acid transport proteins: targeting FATP2 as a
gatekeeper involved in the transport of exogenous
fatty acids†
Paul N. Black,*ab Constance Ahowesso,a David Montefusco,a Nipun Sainia
and Concetta C. DiRusso*ac
The fatty acid transport proteins (FATP) are classified as members of the solute carrier 27 (Slc27) family of
proteins based on their ability to function in the transport of exogenous fatty acids. These proteins, when
localized to the plasma membrane or at intracellular membrane junctions with the endoplasmic reticulum,
function as a gate in the regulated transport of fatty acids and thus represent a therapeutic target to delimit
the acquisition of fatty acids that contribute to disease as in the case of fatty acid overload. To date, FATP1,
FATP2, and FATP4 have been used as targets in the selection of small molecule inhibitors with the goal of
treating insulin resistance and attenuating dietary absorption of fatty acids. Several studies targeting FATP1
and FATP4 for drug development were based on the intrinsic acyl CoA synthetase activity of these proteins
and not on transport directly. While several classes of compounds were identified as potential inhibitors of
fatty acid transport, in vivo studies using a mouse model failed to provide evidence these compounds were
effective in blocking or attenuating fatty acid transport. Our studies targeting FATP2 employed a naturally
occurring splice variant, FATP2b, which lacks intrinsic acyl CoA synthetase due to the deletion of exon 3, yet
is fully functional in fatty acid transport. These studies identified two compounds, 5′-bromo-5-phenyl-spiroĳ3H-
1,3,4-thiadiazole-2,3′-indoline]-2′-one), now referred to as Lipofermata, and 2-benzyl-3-(4-chlorophenyl)-5-
(4-nitrophenyl)pyrazoloĳ1,5-a]pyrimidin-7Ĳ4H)-one, now called Grassofermata, that are effective fatty acid
transport inhibitors both in vitro using a series of model cell lines and in vivo using a mouse model.
Fatty acids and lipotoxic disease
The obesity epidemic is fueled by intake of calorie dense
foods in excess of that needed for growth and development
and to maintain health. Among the nutritional components
correlated with increased disease risk are fats, particularly
saturated and trans-unsaturated fatty acids. Few drugs are
currently available to treat obesity, which is now classified as
a disease affecting 34.9 percent of adults and 16.9 percent of
children and adolescents.1 Of these, most drugs generally
seek to suppress appetite or decrease fat digestion to limit
absorption in the intestine.2–6 A member of the first class is
phenteramine, which is also accompanied by adverse cardio-
vascular events.7–9 Orlistat is a member of the second class of
drugs.10,11 This drug acts to inhibit pancreatic lipase and is
associated with gastrointestinal disturbances. In addition,
the use of orlistat for one year only results in modest weight
reduction. Given the health imperative and economic burden
of the obesity epidemic and the lack of treatment options,
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alternative methods must be found to decrease the preva-
lence of obesity, limit the toxic effects of fatty acids, or inter-
rupt the molecular mechanisms that link excessive accumula-
tion in fatty acids to debilitating diseases.
Chronic imbalances in lipid flux and metabolism often
cause a variety of metabolic abnormalities and pathologies,
including hyperlipidemia, type two diabetes (T2D),
nonalcoholic fatty liver disease (NAFLD), cardiovascular dis-
ease (CVD), and some cancers.12–14 A name given to the cellu-
lar dysfunction caused by high levels of intracellular fatty
acids is lipotoxicity.15–21 For most tissues, the excess fatty
acids are derived from an extracellular source (i.e., diet) when
blood levels of triglycerides and free fatty acids are chroni-
cally elevated. However, de novo synthesis in liver of fatty
acids and triglycerides can also add to the burden of systemic
lipid overload when dietary carbohydrate is consumed chron-
ically at levels above the amount required to meet daily en-
ergy demands. Apart from adipocytes, most cells have a lim-
ited capacity for lipid storage and when this capacity is
exceeded, cell death may result from lipotoxicity character-
ized by ER stress, mitochondrial and nuclear dysfunc-
tion.19,22,23 Obesity is a common initiating condition for
these diseases due to chronic hyperlipidemia and elevated
free fatty acids. Current evidence indicates free fatty acids
and/or their metabolites mediate cell death, although the ex-
act mechanism is poorly understood.22,24–26 Lipid overload in
muscle can lead to insulin resistance and in pancreatic
β-cells may lead to dysregulation of insulin secretion and ap-
optotic cell death, both of which may contribute to the gene-
sis of the diabetic state.27–29 Lipoapoptosis is also observed
in the heart, which leads to the development of heart
failure.30–32 In liver, chronically elevated fat deposits result in
NAFLD, which can lead to steatohepatitis (NASH) and, even-
tually, to non-reversible hepatic cirrhosis.25,33 Therefore,
there is much interest in preventing abnormal lipid accumu-
lation, which can lead to lipotoxicity, metabolic dysfunction,
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and disease. Given the role of free fatty acids in lipotoxicity,
one target to prevent or resolve lipotoxic disease is fatty acid
uptake into cells.
The development of drugs to prevent lipotoxic disease re-
quires the determination components and mechanisms that
contribute to and regulate normal lipid homeostasis, particu-
larly with regard to fatty acid metabolism. Our mechanistic
work has focused on the role of the Slc27a family of proteins
also known as fatty acid transport proteins (FATP).34–40 To
date six family members have been identified in humans,
FATP1-6 (i.e., Slc27a1 through Slc27a6).41 Among these, we
have focused our efforts on FATP2 because of its role in fatty
acid transport and trafficking, especially in liver and intestine
where it is highly expressed. Expression of FATP2 in liver is
consistent with a primary role in fatty acid transport and me-
tabolism; when its expression is increased there is a correla-
tive increase in the progression of NAFLD.42 Recently, FATP2
was identified as a molecular marker for obesity in peripheral
blood mononuclear cells43 and was elevated in livers of ado-
lescents with NASH.44 Decreased expression of FATP2 in liver
using shRNA reduces fatty acid transport and protects mice
from diet-induced NAFLD.45 There is evidence the winged he-
lix/forkhead box (Fox) transcription factor Foxa1 is required
for repression of FATP2; the expression of Foxa1 results in
decreased FATP2 levels and reduced fatty acid uptake in he-
patocytes.46 In this regard Foxa1 expression may function, in
part, to protect liver from steatosis through the regulation of
FATP2. In primary rat hepatocytes the development of
lipotoxicity by palmitate is correlated with increased expres-
sion of plasma membrane localized FATP2 and the develop-
ment of insulin resistance.47 This increase in the expression of
FATP2 in liver is also associated with activation of the insulin
receptor substrates IRS-1 and IRS-2 coincident with lipogene-
sis. The increased levels of FATP2, mediated by IRS signaling,
seem likely to contribute to increased hepatic lipid accumula-
tion and secretion into circulation.48 Given that exogenous
fatty acids directly contribute to NAFLD,49,50 these finding
are of particular importance to inform work directed at
preventing lipotoxicity in susceptible tissues.
Fatty acid transport through vectorial
acylation
Like glucose transport that is coupled to phosphorylation,
one mechanism that drives fatty acid transport into cells is
coupled to esterification with coenzyme A (vectorial acyla-
tion).35 This hypothesis of vectorial acylation, concomitant
fatty acid transport and activation, was put forth by Overath
and co-workers in 1969 and arose from their studies in
E. coli.51 This seminal work demonstrated that a long chain
acyl CoA synthetase (Acsl) is required to target the fatty acids
for metabolism in E. coli. Importantly, these studies demon-
strated that free fatty acids did not accumulate in cells where
fatty acids were provided as the sole carbon and energy
source, but rather acyl CoA derivatives were detected. E. coli
cells lacking the structural gene encoding the Acsl, fadD, are
unable to transport exogenous fatty acids further supporting
this concept. Mechanistically, it is thought the bacterial Acsl
partitions into the inner membrane in response to exogenous
long chain fatty acids where this enzyme abstracts the fatty
acid substrate concomitant with catalysis to produce fatty
acyl CoA.52–55 The resultant acyl-CoA is the ligand of the tran-
scription factor FadR. The FadR-acyl-CoA complex cannot
bind DNA, thus inducing the expression of genes encoding
fatty acid degrading enzymes and the fatty acid transporter
FadL, while also reducing the expression of genes encoding
tow genes required for unsaturated fatty acid biosynthesis.
This foundational work in bacteria describing the process of
vectorial acylation, the generation of long chain acyl CoA and
transcriptional regulatory network has established the basis
for addressing this process in eukaryotic systems.54
In the yeast Saccharomyces cerevisiae, the process of vecto-
rial acylation is operational, but with increased complexity.
The yeast Fat1 protein (Fat1p; YBR041W) was identified by
structural and functional similarities to members of the FATP
family.56 Deletion of the yeast FAT1 gene, encoding Fat1p,
disrupts fatty acid transport measured using both radio-
active substrates and the fluorescent fatty acid analogue,
C1-BODIPY-C12.
56 The reduction in fatty acid transport in
fat1Δ strains is also associated with inability of yeast cells to
grow under conditions where cells are auxotrophic for long
chain fatty acids such as during hypoxia when the fatty acyl
CoA Δ9 desaturase (Ole1p) is inactive. Fat1p-dependent fatty
acid uptake is specific for long chain fatty acids (C16–C20).
Like several mammalian FATPs, Fat1p is a dual functional
protein with acyl CoA synthetase activity specific for very long
chain fatty acids (>C20; Acsvl). Deletion of FAT1 reduces acti-
vation of lignoceric acid (C24:0) and results in the accumula-
tion of very long chain fatty acids.52,57,58 Importantly, alanine
scanning mutagenesis of the yeast FAT1 generated altered
forms of Fat1p that have activities that separate fatty acid
transport from fatty acid activation.59 Three additional lines
of evidence further support the conclusion the transport and
activation activities in different members of the FATP protein
family distinct. First, the expression of FATP1, 2 and 4 in
yeast results in increased Acsvl (i.e., C24:0 or C20:4) activity but
has no affect on Acsl activity using long chain fatty acid sub-
strates (i.e., C14:0 or C18:1).
60 FATP 5 and 6 do not function in
this capacity, nor do they complement transport deficiencies
in yeast fat1Δ strains. Second, the characterization of five dif-
ferent murine FATP1, 4, and 6 protein chimeras distin-
guished fatty acid transport and activation.36 And third, two
splice variants of human FATP2 (2a and 2b) are expressed in
various tissues.35,37,59,61 Variant 2b is missing exon 3
encoding the ATP/AMP binding site and functions in fatty
acid transport but not fatty acid activation.38 The fundamen-
tals of vectorial acylation in yeast and mammals are shown
in Fig. 1 where the formation of acyl CoA drives transport.
While there is evidence that in the case for FATP4, it may
function alone to drive this process,62 the genetic data and
the identification of a catalytically deficient form of FATP2
detailed above supports the proposal that a cognate acyl CoA
MedChemCommReview
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synthetase must function in concert with an FATP to drive
this process.
FATP/Scl27 family members as drug
targets
As summarized above, the fatty acid transport proteins
(FATP) are classified as members of the solute carrier 27
(Slc27) family of proteins35,41,63,64 and have been evaluated
for their ability to promote the transport of exogenous fatty
acids in a number of different cell types.34–36,41,47,56,59,60,62–80
The first fatty acid transport protein, FATP1, as well as Acsl1,
was identified using expression cloning from a cDNA library
prepared from murine 3T3-L1 adipocytes directly demonstrat-
ing its physiological role in the net accumulation of fatty
acids.80 A number of different isoforms of FATP have subse-
quently been identified experimentally in mice, rats, humans,
C. elegans, Drosophila and yeast.56,58,62,63,67,68,78,80–82 In mam-
mals there are six isoforms that differ based on their tissue
and cell type distribution, regulation and preferred sub-
strate.73 While the expression of each of these proteins has
been correlated with increased levels of fatty acid transport,
several have also been described as very long chain acyl CoA
synthetases (Acsvl). Indeed prior to the classification of this
family of proteins as members of the Slc27 family, several
were first described as very long chain acyl CoA synthetases,
and based on their sequence encoding an ATP binding do-
main clearly fall into the larger family of adenylate-forming
enzymes.45,71,82–91 One member of this family, FATP4, plays a
major role in vivo in maintaining the barrier function of the
skin through ceramide metabolism and contributes to the
epidermal barrier function.64,70 Another, FATP5, has activa-
tion activity towards bile acids and is involved in secondary
bile acid metabolism.92,93 Finally, there is evidence these pro-
teins are localized to the endoplasmic reticulum in addition
to the plasma membrane, which may occur at regions of jux-
taposition between the two membranes (e.g., see ref. 94 and 95).
None-the-less, both knockdown and over expression studies of
several members of the FATP family are consistent with the con-
clusion they function in the process governing the transport of
exogenous fatty acids into the cell in a highly regulated manner.
Given their important roles in fatty acid transport, the
FATP proteins are viewed as viable targets to prevent aberrant
accumulation of fat in cells and tissues that leads to lipotoxic
disease. FATP1 and FATP4 have been used to select inhibitors
by high throughput screening.96,97 In each screen, acyl CoA
synthetase activity was targeted and not fatty acid transport
directly. It was rationalized that the Acsl activity was essential
for transport activity due to coupled activation and transport.
However, from our work in yeast, the activation and transport
activities are separable.36,59,61 FATP1 was particularly chosen
as a therapeutic target for the treatment of insulin resistance
and various arylpiperazines were selected as inhibitors.96
However, upon testing in mice, the selected compound
imidazolepyridine did not limit the accumulation of triglycer-
ide in muscle when mice were fed a high fat diet leading to
the conclusion that inhibition of FATP1 alone is insufficient
to block fatty acid transport.96 FATP4 was originally described
as the major FATP in the intestine and the rationale for its
selection as a therapeutic target was to block the absorption
of dietary fatty acids.97 In this case screening studies identi-
fied dihydropyrimidinones as FATP4-specific inhibitors.
Again, in subsequent in vivo studies these compounds were
ineffective as inhibitors of fatty acid absorption. These results
informed our choice to focus on FATP2 and to limit our
screening design to fatty acid transport rather than Acsl
activity.
Fatty acid transport protein 2 (FATP2)
Recent work in our laboratories has focused on FATP2
(Slc27a2), which is expressed in specific tissue types, particu-
larly the small intestine, pancreas and liver.38 FATP2 was orig-
inally defined as a very long chain acyl CoA synthetase (Acsvl1)
with an indirect role in the pathophysiology of X-linked adre-
noleukodystrophy (X-ALD).86,87,98 However, while the FATP2/
Acsvl1 knockout mouse ( fatp2-/-) has reduced very long chain
acyl CoA synthetase (Acsvl) and peroxisomal very long chain
FA oxidation activities in liver, it does not accumulate very
long chain fatty acids in blood, a hallmark of X-ALD. The role
of FATP2 in fatty acid transport was subsequently demon-
strated in both yeast and mammalian cells.37,38,45,60 Of partic-
ular importance was the identification of a splice variant of
FATP2 (FATP2b) that lacks acyl CoA synthetase activity yet is
fully functional in fatty acid transport demonstrating the
transport activity is distinct from fatty acid activation.38
Fig. 1 Models of eukaryotic vectorial acylation. A. FATP and Acsl
function as a complex at the plasma membrane (PM) to drive the
coupled transport and activation of long chain fatty acids. B. FATP and
Acsl form a complex in a region of the endoplasmic reticulum (ER) that
is associated with the plasma membrane to drive the coupled
transport and activation of long chain fatty acids.
MedChemComm Review
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FATP2 is highly expressed in small intestine, liver, kidney,
pancreas and placenta and to a lesser extent in brain, heart,
and colon; expression is not detectable in white adipose tis-
sue38 (see http://www.proteinatlas.org/). FATP2 expression in
the small intestinal mucosa has been confirmed and more-
over was shown to significantly increase in mice fed a high
fat diet.99,100 FATP2 is the predominant FATP isoform expressed
in Caco-2 cells, a human epithelial colorectal adenocarci-
noma cell line.40 Expression of FATP2 in liver is also consis-
tent with a key role in fatty acid transport and metabolism.
In primary rat hepatocytes, the development of lipotoxicity by
palmitate (C16:0) is correlated with increased FATP2 expres-
sion, plasma membrane localization, and the development of
insulin resistance.47 Increased expression is linked with the
progression of nonalcoholic fatty liver disease (NAFLD)42
while decreased expression using adenoviral-directed fatp2
shRNA reduces fatty acid transport and protects mice from
diet-induced NAFLD.45 FATP2 levels increase in isolated hu-
man pancreatic islets under high glucose conditions
supporting a mechanistic basis of this protein in fatty acid
transport in β cells.101 FATP2 is the predominant isoform in
INS-1E cells, a rat pancreatic β cell line.102
The regulation of FATP2 expression is complex. In the
small intestine, FATP2 expression levels are increased four-
to five-fold in response to the PPARα agonists Wy12643 and
GW7647.103 In PPARα null mice, the expression of FATP2 is
decreased two-fold; the expression of FATP2 remains
unchanged in PPARα null mice treated with both agonists.103
There is evidence the winged helix/forkhead box (Fox) tran-
scription factor Foxa1 regulates the expression of FATP2 in
liver. As noted above, the increased expression of Foxa1 in
HepG2 cells and primary human hepatocytes decreases
FATP2 expression, which is correlated with approximately
two-fold lower levels of fatty acid transport.46 In this regard
Foxa1 expression appears to function, in part, to protect liver
from steatosis through the regulation of FATP2. The in-
creased expression of FATP2 in liver is also associated with
activation of the insulin receptor substrates IRS-1 and IRS-2,
which is coincident with increased lipogenesis. Given that ex-
ogenous fatty acids directly contribute to NAFLD, we suggest
FATP2 is a key determinant in the development of a chronic
fatty liver.49,50,104,105 Finally, and of specific interest in the
context of obesity, FATP2 expression in peripheral blood
mononuclear cells of rats fed a hyperlipidemic cafeteria diet
was 33-fold higher than rats fed a lower fat normal caloric
diet, suggesting this protein may be an ideal marker for over-
weight development and lipotoxicity.43 With this information
as a backdrop, the challenge at present is to target FATP2 to
prevent and resolve lipotoxicity using novel small compound
inhibitors to prevent associated pathologies.
Collectively, FATP2 is an attractive target to develop inhibi-
tors that block fatty acid transport for several reasons. First,
expression of FATP2 is specific to a limited number of tis-
sues, but is highly expressed in intestine and liver.41 Thus,
inhibition is predicted to affect absorption, distribution, and
over-accumulation of fatty acids in liver. Second, studies in
animals and cells, as well as in human clinical studies, indi-
cate depression of FATP2 levels in the liver is associated with
decreased fatty acid uptake and is protective for NAFLD.
FATP2 has been suggested as a biomarker for the develop-
ment of overweight and obesity.43,44,46 Third, a complete
germline deletion of FATP2 in mice did not affect develop-
ment, growth, or normal functions,98 while liver-targeted
gene expression knock down was protective of development
of fatty liver induced by high fat diet.45 Thus, FATP2 fulfills
most of the requirements for a good drug target:106 [1] lim-
ited tissue expression and good specificity, [2] demonstrated
target for NAFLD in animals, [3] long-term inhibition should
not affect most normal physiological functions predicting
limited side effects and good tolerability, [4] high throughput
screening directed against the catalytically deficient form has
yielded five candidate compounds and structural families,39
and [5] in vitro and cell-based assays demonstrate the se-
lected FATP2 inhibitors have limited impact on cell viability
and provided good protection from palmitate-induced cellu-
lar dysfunction and death.102
Development of high throughput
screens to identify compounds that
block FATP2
To address this challenge and further understand the role of
the FATP2 in fatty acid transport, activation and intracellular
trafficking, we devised a screening method for small com-
pound inhibitors that relied on the transport of the fluores-
cent long chain fatty acid C1-BODIPY-C12.
107,108 The primary
screening method employed a yeast strain deficient in fatty
acid transport (fat1Δ) and with reduced Acsl activity (faa1Δ).
In this strain we expressed human FATP2b, which functions
in fatty acid transport but is deficient in acyl CoA synthetase
activity.107,108 The selected transport inhibitors are useful as
[1] chemical probes to understand the biochemical mecha-
nisms that govern fatty acid transport into cells, and [2] novel
compounds of therapeutic value to treat pathological states
resulting from, or exacerbated by, fatty acid accumulation in
non-adipose tissue. Hits identified were scrutinized secondar-
ily to eliminate those that were not specific to fatty acid
transport but caused cellular toxicity, permeability, or be-
cause the compound acted as a fluorescence quenching agent
toward the fluorescent fatty acid analogue C1-BODIPY-C12
used in the screening process.39 The final hit list contained
90 compounds that were categorized to five structural fami-
lies. For each family, representatives that passed secondary
screens were further characterized in two mammalian cell
lines: Caco2 cells, a model for intestinal epithelia, and
HepG2 cells, a model for hepatocytes. Dose response curves
were employed to measure an apparent IC50 for fatty acid up-
take selecting only those in the low micromolar range. The
hit compounds were further tested in these cells and were
shown to significantly depress long chain fatty acid transport
using [14C]-oleate (C18:1
cisΔ9), while not affecting the transport
MedChemCommReview
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of glucose. None of the selected compounds disrupted mem-
brane barrier function tested measuring trans-epithelial elec-
trical resistance (TEER) of the Caco2 cell line or decreased to-
tal Acsl activity. The most effective member of each family
(lowest IC50 in Caco2 and HepG2 cells) was then evaluated in
3T3L1 adipocytes.39 In fat cells, the selected compounds had
a relatively high IC50. The rationale was that prevention of ab-
sorption across the intestine and accumulation of fatty acid
in adipocytes would be preventive of lipotoxicity, while accu-
mulation of fatty acid in adipocytes is viewed as protective
and, therefore, should be preserved in any therapeutic ap-
proach to prevention and management of lipotoxic disease.
Among the final hit list, two, CB16.2 called Lipofemata and
CB5 called Grassofermata, were selected as lead hits since
they had the best profiles for features indicative of a high af-
finity and specificity with low toxicity in all our screening as-
says (DiRusso, C. C. and Black, P. N., 2013, Patent US8431582
B2, Inhibitors of fatty acid uptake and methods of use covers
Grassofermata US8263640 B2, covers Lipofermata)107 (Fig. 2).
Lipofermata
The best-characterized inhibitor to date is Lipofermata, 5′-
bromo-5-phenyl-spiroĳ3H-1,3,4-thiadiazole-2,3′-indoline]-2′-
one), which specifically attenuates FATP2-mediated fatty acid
transport without impacting other cellular functions, includ-
ing long chain acyl CoA synthetase activity.39,102 Lipofermata
is highly effective in attenuating fatty acid transport and im-
portantly prevents lipid accumulation in cells that are models
for hepatocytes (HepG2), enterocytes (Caco-2), myocytes
(C2C12) and pancreatic β cells (INS-1E).102 This compound is
10- to 50-fold less effective in inhibiting fatty acid transport
in 3T3L1 adipocytes and human adipocytes, the preferred
lipid storage site.
Lipofermata inhibits the transport of the fluorescent
fatty acid analogues C1-BODIPY-C12 and BODIPY-FL-C16
through a non-competitive process with IC50s in the low
micromolar demonstrating its utility in blocking the trans-
port of long and very long chain fatty acids, respectively.102
These data are consistent with studies using FATP2 over-
expressing and knock-down cell lines treated with isotopically
labeled exogenous fatty acids, which demonstrated this pro-
tein contributes to fatty acid transport through vectorial
acylation.37,38
The saturated fatty acid, palmitate, is a major component
of the western diet and high levels of dietary intake correlate
with a number of life style diseases including type 2 diabetes
and NAFLD.30,109,110 Palmitic acid induces apoptosis in
Fig. 2 Lipofermata and Grassofermata. A. Chemical structure of Lipofermata (CB16.2); B. dose response curve of Lipofermata blocking the
transport of the fluorescent fatty acids C1-BODIPY-C12 in HepG2 cells; C. chemical structure of Grassofermata (CB5); D. dose response curve of
Grassofermata blocking the transport of the fluorescent fatty acids C1-BODIPY-C12 in HepG2 cells.
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Fig. 3 Role of FATP2 in fatty acid transport and homeostasis. A. Normal fatty acid transport in hepatocytes coupled with cellular homeostasis at
the levels of fatty acid oxidation, lipid synthesis and transcriptional regulation. B. Increased fatty acid transport and lipid overload as associated
with cellular dysfunction, noted in red, and associated with mitochondrial dysfunction (increasing reactive oxygen species (ROS) and lost of
cytochrome C); ER stress (reflected by increased levels of ROS and BiP); increased peroxisomal fatty acid oxidation and associated oxidative stress;
dysregulation of transcription (associated with activation of CHOP; an increase in apoptotic proteins and loss of nuclear membrane integrity); all of
which contribute to the activation of the caspase cascade leading to apoptosis. As detailed in the text, treatment of cells under conditions of fatty
acid overload with either Lipofermata or Grassofermata attenuate or eliminate the cellular dysfunctions noted in B.
MedChemCommReview
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pancreatic β-cell lines as well as in hepatocytes.111,112
Lipofermata treatment blocks both palmitate-induced accu-
mulation of lipid droplets and apoptotic cell death in a dose-
dependent manner.102 Chronic exposure of both liver and β
cells to high levels of saturated fatty acids has been shown to
induce apoptosis and disrupt cellular function thereby con-
tributing to the pathogenesis of fatty liver disease (modeled
in Fig. 3)25,33,113 and type 2 diabetes.114 Lipofermata at rela-
tively low concentrations (5–50 μM) promotes survival of
HepG2 and INS-1E cells and protects against palmitic acid-
induced lipotoxicity measured by evaluating ROS, GSH, BiP,
CHOP and caspase-3 levels).102 On the basis of these find-
ings, we propose Lipofermata is likely to be useful to attenu-
ate cellular and organ lipotoxicity, which leads to disease and
may be of therapeutic use in protecting β cells against
lipotoxicity caused by diets high in saturated fat.
One of the predicted uses of Lipofermata is as an inhibitor
of intestinal fatty acid absorption for use in mechanistic
studies in animals and, perhaps eventually, as a therapeutic.
Lipofermata attenuates fatty acid absorption across the gut
by 80% in a temporal manner.102 There are no other com-
pounds that inhibit fatty acid absorption specifically
targeting fatty acid transport. Xenical (orlistat) is an approved
drug for use in inhibiting fat absorption11 that function by
inhibiting pancreatic lipase and thus triglyceride break-
down.115 In this case, since the fatty acids are not released
from the complex lipid, they cannot be absorbed. It is worth
speculating that Lipofermata may be used as a partner with
orlistat, which will further inhibit free fatty acid transport
across the intestinal epithelium. As reviewed above, selected
FATP1 and FATP4 inhibitors do not prevent fatty acid
absorption.96,97
Grassofermata
A second FATP2-inhibitor identified in our high throughput
screen is Grassofermata, 2-benzyl-3-(4-chlorophenyl)-5-(4-
nitrophenyl)pyrazoloĳ1,5-a]pyrimidin-7Ĳ4H)-one.39 Like Lipofer-
mata, Grassofermata is inhibits the transport of fluorescent
fatty acid-analog C1-BODIPY-C12 in various cell lines that are
models for small intestine, liver, pancreatic islets, muscles
and human adipocytes.102 Inhibition by Grassofermata is spe-
cific for long and very long chain fatty acid transport and is
protective effects against palmitic acid induced lipo-
apoptosis.39,116,117 As predicted, treatment of cells with this
compound does not alter medium chain fatty acid transport.
Consistent with in vitro studies, Grassofermata, like Lipo-
fermata when delivered orally, prevents intestinal absorption
of 13C labeled oleate.117 Pharmacokinetic data show this in-
hibitor is detectible in the blood within 30 minutes of dosing
and for up to 6 hours indicating it is absorbed as well.117
Like Lipofermata, Grassofermata is a specific FATP2 fatty
acid transport inhibitor that has valuable potential to add to
our arsenal of pharmaceuticals to prevent and treat lipotoxic
disease.
Prospective
Exogenous long-chain fatty acids contribute to normal meta-
bolic homeostasis that includes energy production, complex
lipid synthesis for membranes and storage, and protein an-
choring. Under normal conditions, excess fatty acids are es-
terified and stored as triglycerides in adipocyte stores that
are dynamically responsive to systemic energy needs. Apart
from adipocytes, most cells have a limited capacity for lipid
storage and when this capacity is exceeded, as in the case of
fatty acid overload, cell death may result from a process
called lipotoxicity.17,19,113,118–122 The identification of
Lipofermata (5′-bromo-5-phenyl-spiroĳ3H-1,3,4-thiadiazole-2,3′-
indoline]-2′-one)) and Grassofermata (2-benzyl-3-(4-chloro-
phenyl)-5-(4-nitrophenyl)pyrazoloĳ1,5-a]pyrimidin-7Ĳ4H)-one),
as effective FATP2 fatty acid transport inhibitors, represents a
key advance in targeting FATP2/Slc27a2 fatty acid transport
protein to combat diseases associated with lipid overload.
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